Active Ingredient History
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma. Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma, Hepatocellular (approved 2022)
Bile Duct Neoplasms (Phase 1/Phase 2)
Biliary Tract Neoplasms (Phase 2)
BRCA1 Protein (Phase 1/Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Merkel Cell (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Pancreatic Ductal (Phase 1)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Cholangiocarcinoma (Phase 2)
Colorectal Neoplasms (Phase 2)
COVID-19 (Phase 2)
Digestive System Diseases (Phase 1)
Drug Interactions (Phase 2)
Drugs, Investigational (Phase 1/Phase 2)
Dysgerminoma (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Fibrosis (Phase 2)
Gallbladder Neoplasms (Phase 2)
Genital Neoplasms, Female (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hematologic Neoplasms (Phase 1/Phase 2)
Hepatitis B virus (Phase 2)
Hepatitis C, Chronic (Phase 2)
HIV (Phase 2)
Hormones (Phase 2)
Hydronephrosis (Early Phase 1)
Hypertension, Portal (Phase 2)
Hypopharynx (Phase 2)
Immunotherapy (Phase 2)
Kidney Neoplasms (Phase 1/Phase 2)
Klatskin Tumor (Phase 2)
Larynx (Phase 2)
Lip (Phase 1)
Liver Neoplasms (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, T-Cell, Cutaneous (Phase 1/Phase 2)
Melanoma (Phase 3)
Menopause (Phase 2)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 2)
Mouth Neoplasms (Phase 1)
Multiple Myeloma (Phase 1)
Multiple Sclerosis (Phase 2)
Mutation (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 1)
Neoplasm Metastasis (Phase 2/Phase 3)
Neoplasms (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplastic Cells, Circulating (Phase 4)
Neuroendocrine Tumors (Phase 2)
Oropharyngeal Neoplasms (Phase 1/Phase 2)
Oropharynx (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Papillomavirus Infections (Phase 1/Phase 2)
Peritoneal Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Rare Diseases (Phase 2)
Sarcoma (Phase 2)
Seminoma (Phase 2)
Sepsis (Phase 1)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 2)
Testicular Neoplasms (Phase 1/Phase 2)
Thyroid Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Ureteral Neoplasms (Early Phase 1)
Urethral Neoplasms (Early Phase 1)
Urinary Bladder Diseases (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 1/Phase 2)
Vaginal Neoplasms (Phase 1)
Vulvar Neoplasms (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
